(Reuters) - U.S. gene-testing company Affymetrix Inc's board on Sunday rejected a $1.5 billion bid by Origin Technologies Corp, saying it stood by a $1.3 billion merger deal with Thermo Fisher ...

A pioneer in microarray technology and a leader in genomics analysis, Affymetrix now develops and provides innovative technologies that enable multiplex and parallel analysis of biological systems at ...

Scientific equipment giant set to acquire developer of genotyping and flow cytometry technology for $1.3 billion amid major backing for new cancer diagnostic efforts. Affymetrix, the ...

Thermo Fisher Scientific Inc. sent a letter to Affymetrix Inc. shareholders on Tuesday, reiterating its argument that its $1.3 billion agreement to acquire the U.S. gene-testing company is superior to ...

(Reuters) - Gene sequencing products maker Affymetrix Inc delayed a shareholder voting on its deal to be acquired by Thermo Fisher Scientific Inc , saying a raised offer from its former executives ...

Can a single word in a 35,000-word merger agreement cause a buyer to lose a deal to a higher bidder? In the case of Thermo Fisher Scientific Inc.’s pending buyout of Affymetrix Inc., it’s possible.

In 2009, Frank Witney became chief executive officer of the fast-growing ion chromatography expert Dionex. Two years later, he sold Dionex to Thermo Fisher Scientific for $2.1 billion. Witney then ...

Offerings Now Encompass Multiplex and Parallel Analysis of Cells, Proteins, and Genes Affymetrix, best known for its pioneering work in commercializing microarrays for gene expression research since ...